Abstract
Pain is a common and disabling non-motor symptom (NMS) of Parkinson’s disease (PD), which occurs through the course of the disease, often unrecognized and undertreated. For this study, we evaluated the efficacy and safety of safinamide to reduce pain in PD patients with motor fluctuations. A total of 13 PD patients with pain receiving safinamide (Xadago®, 100 mg/daily) were prospectively evaluated for 12 weeks. The primary outcome measures were changes in the total score of the King’s Pain Scale for Parkinson’s Disease (KPPS), Brief Pain Inventory (BPI) Intensity and Interference, and the Numeric Rating Scale (NRS). Secondary outcomes were the proportion of pain responders, changes in the Clinical Global Impression of Change (CGI), the Parkinson’s disease Quality of Life 39 (PDQ39), the Unified Parkinson’s Disease Rating Scale parts III and IV (UPDRS III and IV), and laser-evoked potentials (LEPs). LEPs were used to assess potential changes in the central processing of nociceptive inputs. The safety profile was evaluated based on the occurrence of treatment-emergent side effects and the dropout rate. After 12 weeks of add-on safinamide therapy, a significant improvement was noted in the primary (KPPS, BPI Intensity and interference, and NRS) and the secondary outcomes (UPDRS III, IV, CGI, and PDQ39). No significant changes in LEP complexes were observed. All patients completed the study and no treatment-emergent side effects were reported. Our preliminary findings suggest that safinamide 100 mg/day may be effective for the management of pain in PD patients with motor fluctuations and is safe. Further randomized controlled trials are needed to confirm its efficacy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders, 5th edn. Author, Washington
Antonini A, Tinazzi M, Abbruzzese G, Berardelli A, Chaudhuri KR, Defazio G, Ferreira J, Martinez-Martin P, Trenkwalder C, Rascol O (2018) Pain in Parkinson’s disease: facts and uncertainties. Eur J Neurol 25(7):917–e69. https://doi.org/10.1111/ene.13624
Antonini A, Tinazzi M (2015) Targeting pain in Parkinson’s disease. Lancet Neurol 14:1144–5. https://doi.org/10.1016/S1474-4422(15)00286-0
Antonini A, Bauer L, Dohin E, Oertel WH, Rascol O, Reichmann H, Schmid M, Singh P, Tolosa E, Chaudhuri KR (2015) Effects of rotigotine transdermal patch in patients with Parkinson’s disease presenting with non-motor symptoms - results of a double-blind, randomized, placebo-controlled trial. Eur J Neurol 22(10):1400–1407. https://doi.org/10.1111/ene.12757
Barone P (2010) Neurotransmission in Parkinson’s disease: beyond dopamine. Eur J Neurol 17:364–76. https://doi.org/10.1111/j.1468-1331.2009.02900.x
Bhattacharya A, Wickenden AD, Chaplan SR (2009) Sodium channel blockers for the treatment of neuropathic pain. Neurotherapeutics 6:663–78. https://doi.org/10.1016/j.nurt.2009.08.001
Borgohain R, Szasz J, Stanzione P, Meshram C, Bhatt M, Chirilineau D, Stocchi F, Lucini V, Giuliani R, Forrest E, Rice P, Anand R, Study 016 Investigators (2014) Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations. Mov Disord 29:229–37. https://doi.org/10.1002/mds.25751
Borgohain R, Szasz J, Stanzione P, Meshram C, Bhatt MH, Chirilineau D, Stocchi F, Lucini V, Giuliani R, Forrest E, Rice P, Anand R, Study 018 Investigators (2014) Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson's disease. Mov Disord 29:1273–80. https://doi.org/10.1002/mds.25961
Breivik H, Borchgrevink PC, Allen SM, Rosseland LA, Romundstad L, Hals EK, Kvarstein G, Stubhaug A (2008) Assessment of pain. Br J Anaesth 101(1):17–24. https://doi.org/10.1093/bja/aen103
Busner J, Targum SD (2007) The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont) 4:28–37
Caccia C, Maj R, Calabresi M, Maestroni S, Faravelli L, Curatolo L, Salvati P, Fariello RG (2006) Safinamide: from molecular targets to a new anti-Parkinson drug. Neurology 67:S18–23. https://doi.org/10.1212/wnl.67.7_suppl_2.s18
Caraceni A, Mendoza TR, Mencaglia E, Baratella C, Edwards K, Forjaz MJ, Martini C, Serlin RC, de Conno F, Cleeland CS (1996) A validation study of an Italian version of the Brief Pain Inventory (Breve Questionario per la Valutazione del Dolore). Pain 65:87–92. https://doi.org/10.1016/0304-3959(95)00156-5
Cattaneo C, Barone P, Bonizzoni E, Sardina M (2017) Effects of Safinamide on pain in fluctuating Parkinson's disease patients: a post-hoc analysis. J Parkinsons Dis 7:95–101. https://doi.org/10.3233/JPD-160911
Cattaneo C, Kulisevsky J, Tubazio V, Castellani P (2018) Long-term efficacy of safinamide on Parkinson's disease chronic pain. Adv Ther 35:515–522
Chaudhuri KR, Rizos A, Trenkwalder C, Rascol O, Pal S, Martino D, Carroll C, Paviour D, Falup-Pecurariu C, Kessel B, Silverdale M, Todorova A, Sauerbier A, Odin P, Antonini A, Martinez-Martin P, EUROPAR, and the IPMDS Non Motor PD Study Group (2015) King's Parkinson's disease pain scale, the first scale for pain in PD: An international validation. Mov Disord 30:1623–31. https://doi.org/10.1002/mds.26270
Deeks ED (2015) Safinamide: first global approval. Drugs 75:705–11. https://doi.org/10.1007/s40265-015-0389-7
Defazio G, Berardelli A, Fabbrini G, Martino D, Fincati E, Fiaschi A, Moretto G, Abbruzzese G, Marchese R, Bonuccelli U, Del Dotto P, Barone P, De Vivo E, Albanese A, Antonini A, Canesi M, Lopiano L, Zibetti M, Nappi G, Martignoni E, Lamberti P, Tinazzi M (2008) Pain as a nonmotor symptom of Parkinson disease: evidence from a case-control study. Arch Neurol 65:1191–4. https://doi.org/10.1001/archneurol.2008.2
Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole RM (2001) Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 94(2):149–158. https://doi.org/10.1016/s0304-3959(01)00349-9
Ford B (2010) Pain in Parkinson's disease. Mov Disord Suppl 1:S98–103. https://doi.org/10.1002/mds.22716
Galeoto G, Colalelli F, Massai P, Berardi A, Tofani M, Pierantozzi M, Servadio A, Fabbrini A, Fabbrini G (2018) Quality of life in Parkinson's disease: Italian validation of the Parkinson's Disease Questionnaire (PDQ-39-IT). Neurol Sci 39:1903–1909. https://doi.org/10.1007/s10072-018-3524-x
Garcia-Larrea L (2012) Objective pain diagnostics: clinical neurophysiology. Neurophysiol Clin 42:187–97. https://doi.org/10.1016/j.neucli.2012.03.001
Garcia-Larrea L, Convers P, Magnin M, André-Obadia N, Peyron R, Laurent B, Mauguière F (2002) Laser-evoked potential abnormalities in central pain patients: the influence of spontaneous and provoked pain. Brain 125:2766–81. https://doi.org/10.1093/brain/awf275
Geroin C, Gandolfi M, Bruno V, Smania N, Tinazzi M (2016) Integrated approach for pain management in Parkinson disease. Curr Neurol Neurosci Rep 16:28. https://doi.org/10.1007/s11910-016-0628-7
Ha AD, Jankovic J (2012) Pain in Parkinson's disease. Mov Disord 27:485–91. https://doi.org/10.1002/mds.23959
Kassubek J, Chaudhuri KR, Zesiewicz T, Surmann E, Boroojerdi B, Moran K, Ghys L, Trenkwalder C (2014) Rotigotine transdermal system and evaluation of pain in patients with Parkinson's disease: a post hoc analysis of the RECOVER study. BMC Neurol 14:42. https://doi.org/10.1186/1471-2377-14-42
Lim SY, Farrell MJ, Gibson SJ, Helme RD, Lang AE, Evans AH (2008) Do dyskinesia and pain share common pathophysiological mechanisms in Parkinson's disease? Mov Disord 23:1689–95. https://doi.org/10.1002/mds.22111
Lin CH, Chaudhuri KR, Fan JY, Ko CI, Rizos A, Chang CW, Lin HI, Wu YR (2017) Depression and Catechol-O-methyltransferase (COMT) genetic variants are associated with pain in Parkinson's disease. Scient Rep 7(1):6306. https://doi.org/10.1038/s41598-017-06782-z
Movement Disorder Society Task Force on Rating Scales for Parkinson's Disease (2003) The Unified Parkinson's Disease Rating Scale (UPDRS): status and recommendations. Mov Disord 18:738–750. https://doi.org/10.1002/mds.10473
Perez-Lloret S, Ciampi de Andrade D, Lyons KE, Rodríguez-Blázquez C, Chaudhuri KR, Members of the MDS Committee on Rating Scales Development et al (2016) Rating Scales for Pain in Parkinson's Disease: Critique and Recommendations. Mov Disord Clin Pract 3:527–537. https://doi.org/10.1002/mdc3.12384
Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, Obeso J, Marek K, Litvan I, Lang AE, Halliday G, Goetz CG, Gasser T, Dubois B, Chan P, Bloem BR, Adler CH, Deuschl G (2015) MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord 30:1591–601
Qureshi AR, Rana AQ, Malik SH, Rizvi SFH, Akhter S, Vannabouathong C, Sarfraz Z, Rana R (2018) Comprehensive examination of therapies for pain in Parkinson's disease: a systematic review and meta-analysis. Neuroepidemiology 51:190–206. https://doi.org/10.1159/000492221
Rascol O, Zesiewicz T, Chaudhuri KR, Asgharnejad M, Surmann E, Dohin E, Nilius S, Bauer L (2016) A randomized controlled exploratory pilot study to evaluate the effect of rotigotine transdermal patch on Parkinson's disease-associated chronic pain. J Clin Pharmacol 56(7):852–861. https://doi.org/10.1002/jcph.678
Rogers M, Tang L, Madge DJ, Stevens EB (2006) The role of sodium channels in neuropathic pain. Semin Cell Dev Biol 17:571–81. https://doi.org/10.1016/j.semcdb.2006.10.009
Rukavina K, Leta V, Sportelli C, Buhidma Y, Duty S, Malcangio M, Ray Chaudhuri K (2019) Pain in Parkinson's disease: new concepts in pathogenesis and treatment. Curr Opin Neurol 32(4):579–588. https://doi.org/10.1097/WCO.0000000000000711
Schapira AH, Fox SH, Hauser RA, Jankovic J, Jost WH, Kenney C, Kulisevsky J, Pahwa R, Poewe W, Anand R (2017) Assessment of safety and efficacy of safinamide as a levodopa adjunct in patients with Parkinson disease and motor fluctuations: a randomized clinical trial. JAMA Neurol 74:216–224. https://doi.org/10.1001/jamaneurol.2016.4467
Stocchi F, Borgohain R, Onofrj M, Schapira AH, Bhatt M, Lucini V, Giuliani R, Anand R, Study 015 Investigators (2012) A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson's disease patients. Mov Disord 27:106–12
Teixeira FG, Gago MF, Marques P, Moreira PS, Magalhães R, Sousa N, Salgado AJ (2018) Safinamide: a new hope for Parkinson's disease? Drug Discov Today 23:736–744. https://doi.org/10.1016/j.drudis.2018.01.033
Tinazzi M, Del Vesco C, Fincati E, Ottaviani S, Smania N, Moretto G, Fiaschi A, Martino D, Defazio G (2006) Pain and motor complications in Parkinson's disease. J Neurol Neurosurg Psychiatry 77(7):822–825. https://doi.org/10.1136/jnnp.2005.079053
Tinazzi M, Del Vesco C, Defazio G, Fincati E, Smania N, Moretto G, Fiaschi A, Le Pera D, Valeriani M (2008) Abnormal processing of the nociceptive input in Parkinson's disease: a study with CO2 laser evoked potentials. Pain 136:117–24. https://doi.org/10.1016/j.pain.2007.06.022
Tinazzi M, Recchia S, Simonetto S, Defazio G, Tamburin S, Moretto G, Fiaschi A, Miliucci R, Valeriani M (2009) Hyperalgesia and laser evoked potentials alterations in hemiparkinson: evidence for an abnormal nociceptive processing. J Neurol Sci 276(1–2):153–158. https://doi.org/10.1016/j.jns.2008.09.023
Tinazzi M, Recchia S, Simonetto S, Tamburin S, Defazio G, Fiaschi A, Moretto G, Valeriani M (2010) Muscular pain in Parkinson's disease and nociceptive processing assessed with CO2 laser-evoked potentials. Mov Disord 25:213–20. https://doi.org/10.1002/mds.22932
Trenkwalder C, Chaudhuri KR, Martinez-Martin P, Rascol O, Ehret R, Vališ M, Sátori M, Krygowska-Wajs A, Marti MJ, Reimer K, Oksche A, Lomax M, DeCesare J, Hopp M, PANDA study group (2015) Prolonged-release oxycodone-naloxone for treatment of severe pain in patients with Parkinson's disease (PANDA): a double-blind, randomised, placebo-controlled trial. Lancet Neurol 14(12):1161–1170. https://doi.org/10.1016/S1474-4422(15)00243-4
Valeriani M, Rambaud L, Mauguie`re F (1996) Scalp topography and dipolar source modeling of potentials evoked by CO2 laser stimulation of the hand. Electroencephalogr Clin Neurophysiol 100:343–353. https://doi.org/10.1016/0168-5597(96)95625-7
Valeriani M, Pazzaglia C, Cruccu G, Truini A (2012) Clinical usefulness of laser evoked potentials. Neurophysiol Clin 42:345–53. https://doi.org/10.1016/j.neucli.2012.05.002
Wasner G, Deuschl G (2012) Pains in Parkinson disease–many syndromes under one umbrella. Nat Rev Neurol 8:284–94. https://doi.org/10.1038/nrneurol.2012.54
Williams NM, Hubbard L, Sandor C, Webber C, Hendry H, Lawton M, Carroll C, Chaudhuri KR, Morris H, Hu MT, Grosset DG, Kobylecki C, Silverdale M, UK Parkinson's Pain Study (2020) Genome-Wide Association Study of Pain in Parkinson's Disease Implicates TRPM8 as a Risk Factor. Move Dis 35(4):705–707. https://doi.org/10.1002/mds.28001
Zambito-Marsala S, Erro R, Bacchin R, Fornasier A, Fabris F, Lo Cascio C, Ferracci F, Morgante F, Tinazzi M (2017) Abnormal nociceptive processing occurs centrally and not peripherally in pain-free Parkinson disease patients: A study with laser-evoked potentials. Parkinsonism Relat Disord 34:43–48. https://doi.org/10.1016/j.parkreldis.2016.10.019
Funding
This work was supported by ZAMBON Italy.
Author information
Authors and Affiliations
Contributions
Conceptualization and methodology: MT; data collection: CG, AS, GS; statistical evaluation and interpretation: CG, MT, IDV, GS; writing—original draft preparation: CG, MT; writing—review and editing: IDV, GS, AS, TB; project supervision: MT.
Corresponding authors
Ethics declarations
Conflict of interest:
None.
Ethical approval
The institutional review board reviewed and approved the study protocol. All patients (or their guardians) were informed about the nature of the study and gave their written consent to participate. The study was registered at https://clinicaltrials.gov (NCT03648671, August 27, 2018).
Consent to participate
All patients gave written informed consent prior to their inclusion in the study.
Consent for publication
All authors gave consent for publication of this manuscript.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Geroin, C., Di Vico, I.A., Squintani, G. et al. Effects of safinamide on pain in Parkinson’s disease with motor fluctuations: an exploratory study. J Neural Transm 127, 1143–1152 (2020). https://doi.org/10.1007/s00702-020-02218-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00702-020-02218-7